SCHEMBL27850282

SCHEMBL27850282

COC(=O)c1ccccc1Oc1ccc(N2CCC(=O)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.55
▸ CYP2C9 P11712 3/20 0.55
▸ CYP2C19 P33261 3/20 0.55
▸ MAPT P10636 7/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ TSHR P16473 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ CYP1A2 P05177 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ GAA P10253 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ SCN1A P35498 1/20 0.45
▸ SCN2A Q99250 1/20 0.45
▸ SCN3A Q9NY46 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1957162 0.85 CYP2C9 (0.47) KMT2ACYP2C9CYP2C19MAPTMEN1
Bromobenzene SCHEMBL28102861 0.83 KMT2A (0.48) KMT2ACYP2C9CYP2C19MAPTMEN1
SCHEMBL17893779 0.76 HIF1A (0.50) KMT2ACYP2C9CYP2C19MAPTMEN1
SCHEMBL2540179 0.76 CTNNB1 (0.62) KMT2AMAPTMEN1HSD17B10MAPK1
SCHEMBL7715935 0.76 MYC (0.54) KMT2AMAPTMEN1ALDH1A1TSHR
SCHEMBL8782253 0.75 SLC6A3 (0.61) KMT2AMAPTMEN1ALDH1A1TSHR
SCHEMBL27850308 0.75 SLC6A3 (0.64) KMT2ACYP2C19MEN1ALDH1A1TSHR
SCHEMBL432 0.75 MEN1 (0.56) KMT2ACYP2C9CYP2C19MAPTMEN1
SCHEMBL1359510 0.75 ALDH1A1 (0.65) KMT2AMAPTMEN1ALDH1A1TSHR
SCHEMBL17535526 0.75 TDP1 (0.51) KMT2ACYP2C9CYP2C19MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102307872-B BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2016-06-15 — — CN disclosed
CN-102947285-A Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases ABBOTT LAB 2013-02-27 — — CN disclosed
CN-102307872-A BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases ABBOTT LAB 2012-01-04 — — CN disclosed
Send feedback